Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa results

besponsa results

Перейти к контенту

Главное меню:

Разное
besponsa results
About BESPONSA® | BESPONSA®, Welcome to BESPONSA® | BESPONSA®, BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , NICE issues decision on Mylotarg, Besponsa for leukaemia , Besponsa (Inotuzumab Ozogamicin) | Lymphoma News Today, Pfizer : NICE okays Pfizer blood cancer drug Besponsa , , , .
BESPONSA is associated with a risk of liver problems and increased risk of death after stem cell transplant. BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they:. BESPONSA is a type of medicine called an antibody-drug conjugate. BESPONSA is designed to find and attach to a specific protein, called CD22, found on leukemia cells BESPONSA is designed to find and attach to a specific protein, called CD22, found on leukemia cells. The Food and Drug Administration approved BESPONSA based on the results of the clinical trial that showed treatment with BESPONSA compared to chemotherapy improved complete remission (CR) rates (36% vs 17%), length of CR (8.0 months vs 4.9 months), and minimal residual disease–negative CR rates (90% vs 32%)..
CLINICAL Study results. The efficacy and safety of BESPONSA were evaluated in a Phase 3 clinical trial vs standard chemotherapy. 1,2 There was a higher post-HSCT non-relapse mortality rate in patients receiving BESPONSA, resulting in a higher Day 100 post-HSCT mortality rate; Hepatotoxicity, Including Hepatic VOD: Hepatotoxicity, including fatal and life-threatening VOD, occurred in 23/164 . The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute lymphoblastic leukaemia (ALL).. Of patients on Besponsa, 81 percent had complete remission, compared to only 29 percent of patients on chemotherapy, according to results published in the New England Journal of Medicine. Furthermore, Besponsa maintained remission for longer (a median of 4.6 months) than chemotherapy (3.1 months).. As a result of this the cost-effectiveness body has now recommended Besponsa, an antibody-drug conjugate, in updated final draft guidance. The decision gives a new treatment option for patients with a disease whose prognosis is poor, and for which there are few available alternative therapies.. . .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню